Judgment issued May 11 in Pfizer's lawsuit against "Vaegra" marketer Institute of Sexual Research/David Brady imposes fines totaling $160,000; trademark infringement suit against sham impotence treatment was filed April 20 ("The Tan Sheet" April 27, p. 18). The judgment also prevents ISR, doing business as "American Urological Clinic," from using in any way the Viagra mark "or any colorable imitations thereof, including the VAEGRA name or mark," as well as the drug name sildenafil or "Celldenaphil-pc." Judgment requires Brady to distribute a letter to mailing list retracting previous false "statements, implications or suggestions." Separately, in a case brought by Missouri Attorney General, a Kansas City circuit court orders ISR to refund purchasers of Vaegra. The May 18 order imposes $167,000 in investigative and civil penalties...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
Rexulti’s post-traumatic stress disorder sNDA tries to make up for a failed Phase III study by placing a Phase II study into a key evidentiary role, raising questions for the July 18 advisory committee meeting about assessing discordant results and post-hoc analyses.
The FDA is pushing the use of novel alternatives to animal models, but the Government Accountability Office said sponsors need more clarity and hopes an upcoming guidance will help.
The Association of the British Pharmaceutical Industry says that while the government’s newly published Life Sciences Sector Plan includes many positive commitments, they are not enough.